Volume 25, Number 4—April 2019
Research
Co-infections in Persons with Early Lyme Disease, New York, USA
Table 2
Age, y | Fever | No. symptoms at baseline visit | Tick exposure in LHV | Tick exposure outside LHV | Baseline B. microti antibody titer | Convalescent-phase B. microti antibody titer (timing, d)† | Blood smear | PCR for Babesia DNA |
---|---|---|---|---|---|---|---|---|
69 |
Yes, but began 4 d after baseline visit while taking amoxicillin for treatment of Lyme disease |
1 |
Yes |
No |
>1:1,024 |
>1:1,024 (12) |
+ |
+ |
58 |
Yes, began 1 or 2 d before the baseline visit |
10 |
Yes |
Yes |
<1:64 |
>1:1,024 (14) |
– |
+ |
61 |
No |
2 |
Yes |
No |
>1:1024 |
>1:1,024 (21) |
– |
+ |
45 |
No |
1 |
Yes |
No |
<1:64 |
1:512 (18) |
ND |
ND |
54 |
No |
2 |
No |
Yes |
>1:1024 |
>1:1,024 (19) |
ND |
ND |
32 | No | 4 | Yes | No | >1:1024 | >1:1,024 (14) | ND | ND |
*LHV, Lower Hudson Valley of New York state, USA (includes Westchester, Putnam, Dutchess, Rockland, Orange, Ulster, and Sullivan Counties); ND, not done; +, positive; –, negative.
†Time from baseline visit.
Page created: March 18, 2019
Page updated: March 18, 2019
Page reviewed: March 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.